PIK3CB and neoplasm: These studies suggest that - low levels of residual HER2 comparable to that in non-HER2-amplified tumours may be sufficient to phosphorylate and activate HER3, subsequently causing PI3K/AKT activation after PI3K/AKT or HER2 inhibition.